Skip to content
Peptide research

Nonapeptide-1

Also known as Melanostatine · Melanostatine-5
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

A synthetic nonapeptide that blocks alpha-MSH at MC1R to reduce melanin, marketed for skin lightening, hyperpigmentation, and melasma maintenance. Human evidence for lightening benefit is low, and claims like even skin tone or a safer hydroquinone alternative remain speculative. Clinical data are limited, pregnancy safety is unknown, and allergic reactions occur. Not an approved drug; supply is unregulated research-grade material.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Nonapeptide-1 (trade name Melanostatine 5) is a synthetic nine-amino-acid peptide used in skin-brightening cosmetics as a gentler alternative to hydroquinone. It works by blocking the tanning signal: when your body sends alpha-MSH to darken the skin, Nonapeptide-1 competitively binds to the MC1R receptor on skin cells, preventing the signal from triggering melanin production. It reduces melanin output by approximately 33% without killing or damaging skin cells. Discovered at Yale University in 1994 and later commercialized by Lucas Meyer Cosmetics, it is widely used in Asian and European skincare markets.

How it works in the body

A synthetic nonapeptide (Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2) that acts as a competitive antagonist of alpha-MSH at the MC1R receptor on melanocytes. By blocking MC1R, it inhibits cAMP accumulation (IC50: 2.5 nM) and downstream melanin synthesis, reducing pigmentation without cytotoxicity.

Research overview

Nonapeptide-1 is a potent MC1R blocker -- at the molecular level, it inhibits the melanin-triggering cAMP signal with an IC50 of just 2.5 nM (extremely low concentration). The original discovery paper (Jayawickreme et al., 1994, Yale) screened approximately 40% of a library containing 31,360 peptide variants to identify it as the most effective melanin-suppressing compound. However, the clinical evidence base is thin: at least two small human trials of combination products have been published. Most efficacy claims come from lab studies and proprietary data from cosmetic ingredient suppliers. While the mechanism is well-understood, robust independent human trials are lacking.

Who researches Nonapeptide-1?

Commonly researched by

  • People researching skin health and rejuvenation

    Studied for collagen synthesis, skin repair, or anti-aging skin effects.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(4)

Rated by level of concern

  • Limited human clinical data

    High

    Human combination trials: PMID 34379946 and DOI 10.1111/jocd.70329; neither isolates nonapeptide-1.

  • Allergic contact dermatitis

    Low

    PMID 34379946; no case reports or patch-test series identified

  • Unknown pregnancy/lactation safety

    Moderate

    No primary source identified (absence-of-evidence claim)

  • Unregulated product quality

    Moderate

    Cosmetic (non-drug) regulatory status; nonapeptide-1 supplied as acetate salt per PMID 35645678

Interaction summary(8)

Rated by direction with this peptide

  • Afamelanotide (SCENESSE) and other MC1R agonists

    CautionTheoretical

    Direct pharmacodynamic opposition in principle - nonapeptide-1 is characterized as a competitive MC1R antagonist at the site afamelanotide activates, so concurrent use could in theory blunt the intended photoprotective tanning response in erythropoietic protoporphyria. Entirely mechanistic: afamelanotide is a systemic implant while nonapeptide-1 is a topical cosmetic with minimal expected systemic exposure, and no interaction has ever been reported or studied.

    Mechanistic (MC1R competitive antagonism); afamelanotide prescribing information. Commonly quoted MC1R potency figures for nonapeptide-1 come from ingredient-supplier literature, not peer-reviewed data.

  • Melanotan I/II and other unregulated melanocortin tanning peptides

    CautionTheoretical

    Same receptor, opposite direction - the two agents would be expected to oppose each other, and neither the agonist nor the antagonist has human safety data supporting combined use. Mechanistic inference only; no reports exist.

    Mechanistic (shared MC1R target); no clinical reports identified

  • Broad-spectrum sunscreen

    SynergisticLow

    UV is the upstream driver of alpha-MSH release, so photoprotection removes the stimulus the peptide is antagonizing. The only human RCT delivered nonapeptide-1 in a sunscreen-containing vehicle and compared it against sunscreen alone; the added benefit over sunscreen alone was not statistically significant, so this is a rational pairing rather than a demonstrated synergy.

    PMID 34379946

  • Hydroquinone / triple-combination cream (hydroquinone-tretinoin-fluocinolone)

    SynergisticLow

    Mechanistically complementary targets - hydroquinone acts on tyrosinase inside the melanocyte while nonapeptide-1 is proposed to block the receptor upstream. Important caveat: the pilot RCT used the nonapeptide-1 product sequentially, as maintenance after triple-combination induction, not concurrently, so concurrent-use data do not exist.

    PMID 34379946 (sequential maintenance design)

  • Topical retinoids (tretinoin, adapalene, retinol)

    CautionLow

    Additive depigmenting benefit is plausible, but added retinoid irritation and barrier disruption can provoke post-inflammatory hyperpigmentation in darker phototypes, which works against the goal. General dermatologic principle, not specific to this peptide.

    Mechanistic; general melasma-therapy practice

  • Alpha/beta hydroxy acids and chemical peels

    CautionLow

    Layering exfoliants increases penetration and irritation risk; in melasma-prone skin irritation-driven post-inflammatory hyperpigmentation can offset any lightening effect. General dermatologic principle, not specific to this peptide.

    Mechanistic; general melasma-therapy practice

  • Photosensitizing drugs (doxycycline, thiazides, amiodarone, voriconazole)

    CautionTheoretical

    Suppressing melanogenesis might modestly reduce constitutive melanin photoprotection while a photosensitizer raises UV reactivity - a mechanistic concern only, never demonstrated for this peptide (which has not been shown to meaningfully reduce melanin in humans at all), and readily managed with strict photoprotection.

    Mechanistic (reduced melanin synthesis); no clinical reports identified

  • Phenylethyl resorcinol and aminoethyl phosphinic acid

    NeutralLow

    These are the co-formulants in the only human trial. Phenylethyl resorcinol is a tyrosinase inhibitor; aminoethyl phosphinic acid is reported in cosmetic-ingredient literature to interfere with melanosome transfer. Reclassified from Synergistic to Neutral: that trial's primary comparisons were not statistically significant, so no synergy was actually demonstrated - the entry documents co-formulation and the resulting attribution problem, not an established beneficial interaction.

    PMID 34379946

Known risks(4)

  • Limited human clinical data

    Moderate

    At least two small human trials tested combination products. Evidence for nonapeptide-1 alone remains limited.

  • Allergic contact dermatitis

    Low

    Uncommon but possible in sensitive individuals.

  • Unknown pregnancy/lactation safety

    Low-Moderate

    No studies evaluated safety during pregnancy or breastfeeding.

  • Unregulated product quality

    Moderate

    As a cosmetic ingredient, actual peptide concentration varies between manufacturers.

Drug interactions(3)

  • Other depigmenting agents (hydroquinone, arbutin, kojic acid)

    Potentially additive/synergistic. Safe to combine; monitor for over-depigmentation.

  • Topical retinoids

    Compatible and complementary. Retinoids may enhance peptide penetration.

  • Systemic medications

    No known systemic drug interactions. Minimal systemic absorption from topical application.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
5
Human Studies
2

Evidence for nonapeptide-1 alone remains largely preclinical. At least two small human trials tested combination products; neither isolates this peptide's effects.

Researched for(6)

Rated by confidence in the evidence

  • Skin lightening and brightening

    Low

    Melanin-blocking mechanism confirmed in cell and rodent studies; not tested alone in humans.

    PMID 35645678 (Postepy Dermatol Alergol 2022, comparator arm); PMID 39260749 (Int J Pharm 2024, peptide used as conjugation ligand)

  • Hyperpigmentation reduction

    Low

    Cell and animal data show reduced melanin; a small multi-ingredient human trial was not significant.

    PMID 35645678; PMID 34379946 (Indian J Dermatol Venereol Leprol 2021)

  • Even skin tone

    Speculative

    No study has measured tone evenness; this is inferred from melanin-reduction data only.

    No primary source identified

  • Safe alternative to hydroquinone

    Speculative

    A small trial compared combination products alongside oral tranexamic acid; it did not isolate nonapeptide-1.

    PMID 34379946

  • Anti-photoaging support

    Speculative

    Only supporting study used it as a nanoparticle carrier, not the active ingredient; no human data.

    PMID 39260749

  • Melasma maintenance therapy

    Low

    One small multi-ingredient human pilot trial (n=46) trended positive but missed significance.

    PMID 34379946

Benefits(6)

  • Skin lightening and brightening

    Reduces melanin synthesis by ~33% through MC1R antagonism. Jayawickreme et al. 1994.

  • Hyperpigmentation reduction

    Proprietary studies report visible improvement in 28 days.

  • Even skin tone

    Blocks localized overproduction of melanin in hyperpigmented areas.

  • Safe alternative to hydroquinone

    Limited combination-product studies do not establish absence of irritation or rare harms.

  • Anti-photoaging support

    Huang et al. 2024: conjugated nanoparticles enhanced UV protection and reversed photoaging markers.

  • Melasma maintenance therapy

    Chatterjee et al. 2021: pilot RCT showed MASI score reduction in proprietary combination post-triple-combination therapy.

Key studies(3)

  1. Discovery and structure-function analysis of alpha-melanocyte-stimulating hormone antagonists

    In vitro / Combinatorial library screening31,360 peptide library

    Jayawickreme CK, Quillan JM, Graminski GF, Lerner MR

    Journal of Biological Chemistry

    1994

    Identified Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2 as the most potent alpha-MSH antagonist with IC50 of 11 nM.

  2. Chatterjee M, Neema S, Rajput GR

    Indian Journal of Dermatology, Venereology and Leprology

    2021

    Proprietary combination showed consistent MASI score reduction vs sunscreen alone, though did not reach statistical significance.

  3. Huang ZJ, Zhou XH, Wen WQ, et al.

    International Journal of Pharmaceutics

    2024

    Nonapeptide-1-conjugated nanoparticles achieved melanin inhibition 5.22x that of free EGCG.

Regulation & availability

Why researchers look at it

Identified as the most potent antagonist in a Yale screen of approximately 40% of a 31,360-member peptide library, with an IC50 of just 2.5 nM — a gentler alternative to hydroquinone that blocks the tanning signal rather than killing melanocytes. The 46-subject maintenance trial did not reach statistical significance; another small combination-product trial appeared in 2025, leaving real-world efficacy largely unproven despite widespread commercial use.

Estimated cost
$20-60/mo in OTC serums
FDA status
Not FDA-approved as a drug. Has FDA UNII code 64W45420K5. Regulated as a cosmetic ingredient under the FD&C Act. No NDA, IND, or drug approval pathway pursued.
WADA status
Not listed on the WADA Prohibited List. No performance-enhancing properties. Used exclusively as a topical cosmetic.
Prescribability
Not prescribed as a drug. Nonapeptide-1 is classified as a cosmetic ingredient, not a pharmaceutical. Available over-the-counter in topical skincare products (serums, creams, lotions) without prescription. No FDA drug approval. Products containing it are regulated as cosmetics.
Availability
Widely available OTC in topical skincare products worldwide. Found in serums, creams from brands including RoC, BIOCHEM, and various Korean skincare brands. Commercial trade name Melanostatine 5 BG supplied by Lucas Meyer Cosmetics (IFF). No prescription required.

International status

  • EU

    Available OTC in cosmetics (INCI listed)

  • US

    Available OTC in cosmetic products (not a drug)

  • Worldwide

    Regulated as cosmetic ingredient, not pharmaceutical

Regulatory timeline(4)

  1. 1994
    Discovery by Jayawickreme et al. at Yale University from 31,360-member combinatorial peptide library.
  2. Late 1990s-2000s
    Commercialized as Melanostatine 5 BG by Lucas Meyer Cosmetics for cosmetic skin-brightening.
  3. 2021
    First published human RCT (Chatterjee et al.) — 46 subjects, melasma maintenance.
  4. 2024
    Huang et al. publish nanoparticle conjugation study using nonapeptide-1 as melanocyte-targeting ligand.

Sources & FAQs

Research sources(5)

Frequently asked questions(5)

How does Nonapeptide-1 differ from hydroquinone?

Nonapeptide-1 blocks the alpha-MSH signal at MC1R, preventing melanin overproduction at the signaling level. Hydroquinone directly inhibits tyrosinase and can be cytotoxic. Nonapeptide-1 is gentler but less proven in clinical trials.

How long does it take to show results?

Proprietary studies report visible improvement in skin tone within 28 days of consistent twice-daily application.

Is it safe for all skin types?

Small combination-product studies suggest tolerability, but safety for every skin type is not established at standard cosmetic concentrations (0.5-4%).

Can it be used with other skincare actives?

Yes, compatible with niacinamide, vitamin C, retinol, hyaluronic acid, and AHAs. Works through a different mechanism than most brightening agents.

Is Nonapeptide-1 the same as melanotan?

No. They have opposite effects. Nonapeptide-1 is an MC1R antagonist (blocks melanin, lightens skin). Melanotan is an MC1R agonist (stimulates melanin, darkens skin).